Prostaglandin E 2 (PGE 2 ) induces bone formation in stress-bearing bones. The mandible, a stress-bearing bone, is loaded daily during mastication. The aim of this study was to determine if PGE 2 delivered locally to the mandible over 20 days enhances alveolar bone deposition. In 18 Lewis rats, controlled-release pellets containing PGE 2 were implanted on the buccal aspect on the left-hand side of the mandible, mesial to the root of the first molar. Controlled-release pellets locally delivered 0.1, 0.05, or 0.025 mg/day of PGE 2 . The right side of the mandible was used as a matched control for each animal. Six sham-treated animals were implanted with a placebo pellet. On days 7 and 19, animals were injected with the bone markers tetracycline and calcein, respectively. On day 21, animals were sacrificed and undecalcified tissues obtained for morphometrical analysis. Morphometrical measurements were analyzed by paired t test to determine differences between the matched samples and one-way ANOVA to compare the different treatment groups. A significant increase in alveolar bone area was observed in mandibles treated with 0.1 and 0.05 mg/day when compared with matched controls and the placebo group. This was accompanied by a significant increase in alveolar bone height and width. The proportions of double-labeled surface (dLS), the mineral apposition rate (MAR), and bone formation rate (BFR) were significantly increased in mandibles treated with the two higher doses of PGE 2 . The proportion of resorptive surface (RS) was significantly reduced in these two groups. It is concluded that PGE 2 induces alveolar bone formation in the mandible when locally delivered at a dose of 0.1 or 0.05 mg/day for 20 days.
Introduction
Bone is a highly dynamic tissue undergoing continuous turn over under the influence of the local environment. Prostaglandin E 2 (PGE 2 ), a derivative of arachidonic acid [5] , induces periosteal and endocortical bone formation, principally by stimulating local osteoprogenitor cells on the adjacent endocortical surface [3, 21] . Recently, studies have also shown that the response of bone cells to PGE 2 is related to the dose and route of administration [3, 16] .
The anabolic effect of PGE 2 demonstrated in long bones may also occur in the mandible. Particularly as local delivery of prostaglandin E1 (PGE1) has been shown to enhance the formation of mandibular alveolar bone, reorganization of adjacent cells in the periodontal ligament and cementum formation [11, 13, 18] . The positive effect of PGE 2 on bone deposition has been reported with doses as low as 1 mg/kg per day delivered subcutaneously into different animal models over extended periods of time [1, 6, 9, 20] . In load-bearing bones, PGE 2 has an anabolic effect when administered either systemically or locally [7] . In addition, the dose of PGE 2 required to prevent bone loss in ovariectomized rats may be reduced if PGE 2 treatment is accompanied with exercise [15] . As the mandible bexercisesQ through mastication, it is hypothesized that PGE 2 stimulates higher rates of alveolar bone deposition when delivered locally to the mandible. Bone deposition stimulated by an external agent (i.e., PGE 2 ) may be extended for up to 20 days, which is the duration of the remodeling cycle in long bones [8] and the period required by cultured progenitor osteoblasts to differentiate and mature [2] , even though the remodeling cycle in the mandibular alveolar bone appears to run faster [19] . Therefore, the aim of this study is to determine if PGE 2 locally delivered to the mandible over 20 days stimulates alveolar bone formation in the rat mandible.
Materials and methods
Twenty-four, 12-week-old, female Lewis rats were obtained from the Animal Resource Centre at the University of Western Australia. The animals were weighed at the beginning and at the end of the experiment. Ethical approval for the study was obtained from the University of Queensland Animal Experimentation Ethics Committee (DENT/ 046/02/NHMRC).
Pellet implantation
The animals were divided into four groups for treatment with either PGE 2 or placebo. Each group was composed by six animals. A PGE 2 -controlled release pellet or a placebo pellet (Innovative Research of America, Toledo, OH) was implanted on the buccal aspect on the left mandible adjacent to the mesial root of the first molar. For implantation of pellets, rats were anaesthetized with a single intraperitoneal injection of Xylazil/Ketamine (100 mg/kg). An incision of approximately 0.5 cm was made at the lower border of the mandible, tissue reflected to expose the masseter muscle that was displaced distally to reveal the alveolar bone covering the roots of the first molar. The surgical site was sutured with silk (3/0) ligature following placement of the pellet. The experimental animals were implanted with a controlledrelease pellet delivering a dose of 0.1, 0.05, or 0.025 mg of PGE 2 per day over a 20-day period. In the sham-treated group, a placebo pellet (Innovative Research of America) containing the carrier, but no PGE 2 , was implanted.
Seven days following pellet insertion, rats were injected intraperitoneally with tetracycline hydrochloride (SIGMA T-3383, 30 mg/kg) to mark sites of bone formation. At day 19 post-pellet implantation, animals were injected with a second bone marker calcein (SIGMA C-0875 10 mg/kg). Animals were monitored during the experimental time for adverse reactions such as redness on paws or ears, weakness, or inflammation in the area of pellet implantation. All rats were maintained under the same conditions and consumed a normal diet.
Twenty-one days following pellet implantation, intracardiac perfusion was performed with fixative (4% Paraformaldehyde in 0.1 M phosphate-buffered saline (PBS)), and the rats sacrificed by exsanguination. Mandibles were harvested and placed into the same fixative for 4 h. The mandibles were separated into left (experimental) and right (nonexperimental) sides.
Before implantation, pellets were tested for PGE 2 release. Pellets containing placebo and the three doses of PGE 2 were incubated in culture media (DMEM; GIBCO Cat No. 12100-061), and the supernatant collected at days 3, 5, 7, and 10. The concentration of PGE 2 in the supernatant was determined by ELISA (Cayman Chemical, Ann Arbor MI, USA, Cat No. 514010).
Hard tissue sections
Hemi-mandibles were embedded in acrylic resin (LR White medium grade, The London Resin Company, UK). Undecalcified transverse serial sections (90-100 Am) were cut perpendicular to the occlusal plane, in a bucco-lingual direction, using a hard tissue microtome (Leitz saw microtome 1600, Oberkochen-Germany). Transverse bucco-lingual sections of the mesial root of the first molar tooth were obtained and mounted on glass slides. Hard tissue sections were standardized so that each section included the total length of the crown, total length of the root (including the pulp chamber from the crown to the apex), alveolar bone on the buccal and the lingual aspects, and crypt of the incisor tooth including the lower margin (Fig. 1) . One standardized section per hemi-mandible was obtained.
Mounted hard tissue sections were photographed using a digital camera (Nikon Coolpix 995, Japan) mounted on a polarized microscope (Olympus, Tokyo, Japan). Photography was performed at a magnification of 2.5Â. Images were transferred to a computer (Pentium III, 1 GHz processor, 256 Mb RAM, 32 Mb video card) and analyzed using computerized image analyzer software (Scion image Beta 4.0.2, Scion Corp, Maryland, USA), precalibrated with a 1-mm scalar taken under the same conditions. Undecalcified tissue sections from each group were stained with hematoxylin and eosin (H&E) to determine if an inflammatory reaction was evident in tissues adjacent to the site of pellet implantation.
Bone histomorphometry
For this purpose, a vertical line was drawn along the long axis of the first molar, from the center of the occlusal surface of the crown (bucco-lingual) to the center of the aperture at the root apex. A horizontal line, perpendicular to the long axis and tangential to the bone margin on the superior aspect of the bone crypt of the incisor, was drawn on the digitized picture ( Fig. 1) . The area of alveolar bone measured was buccal to the vertical line and superior to the horizontal line on the buccal aspect of the mesial root of the lower first molar. Height and width of the alveolar bone were also determined at the same area. Alveolar bone height was determined by measuring the distance from the horizontal line to the tip of the alveolar bone just beneath the oral epithelium ( Fig. 1 , line c). Alveolar bone width was measured at two points. The first measurement was in the mid region of the alveolar bone area, taking as landmark the dentino-cementum junction. The distance was measured between the internal (facing the periodontal ligament) and the external (facing the periosteum) borders of the alveolar bone (Awa) (Fig. 1, line d) . The second measurement was in the apical region of the alveolar bone area. The distance was measured from the point where the long axis of the tooth intersects with the base of the alveolar socket to the external border of the alveolar bone (Awp) (Fig. 1 , line e). Both alveolar width measurements were perpendicular to the long axis of the tooth.
Fluorescent bone markers
To determine the distribution of the bone markers on the buccal aspect of the first molar root, sections were observed using ultraviolet fluorescence microscopy (Olympus BX60). Digitized pictures at 2.5Â magnification were taken of each sample (Nikon Coolpix995). The buccal region used for measurements on the digitized images was as described above. The perimeter of the surface labeled by the two bone markers, the distance between the double labeling, and the perimeter of the resorptive lacunae were measured on the external and the internal surfaces of the alveolar bone on the buccal aspect of the mesial root (Fig. 2) . These measurements were used to determine indices of bone remodeling. Hard tissue sections from mandibles not injected with tetracycline were used as negative controls.
Bone remodeling indices
Four histomorphometric indices were used in this study to analyze bone biopsy samples [4, 12] . The proportion of the double-labeled surface (dLS) was determined by dividing the perimeter of alveolar surface labeled by the two bone markers over the total perimeter of the measured area and expressed as percentage. Mineral apposition rate (MAR) was calculated by dividing the distance between the two fluorescent labels by the time between the application of the two bone markers (12 days). MAR was expressed as Am/day. Bone formation rate (BFR) was calculated by multiplying the perimeter of dLS times the MAR and expressed in Am 2 /day. The last index used was the proportion of resorptive surface (RS). It was determined by dividing the sum of the perimeters of the resorptive lacunae by the total perimeter of the measured area and expressed as a percentage.
Data analysis
Each measurement was performed twice on different days (gap of 7 days) by the same operator. The data from both measurements were analyzed by Spearman correlation test to determine the level of agreement between them. A high agreement (r N 0.95) was observed between the two sets of measurements. An average from both sets of measurements was used for analysis. The data obtained from the PGE 2 -and placebo-stimulated hemi-mandibles were compared with their matched nonexperimental hemi-mandibles using paired t test. One-way analysis of variance (ANOVA) was used to determine statistical differences between the nonexperimental sides, PGE 2 , and sham-treated groups.
Results
The animals showed neither discomfort nor adverse reactions to the carrier or drug contained in the pellet over the duration of the experiment. All animals gained weight over the experimental period. The average weight at the beginning was 204.8 g (F2.07 SD), and just before euthanasia, 233.2 g (F3.11 SD). ELISA for testing pellet release showed a steady release of PGE 2 into the media for the testing periods (data not shown). Thus, constant daily release of PGE 2 was confirmed from the controlled-release pellets.
Alveolar bone area
Histological sections stained with H&E demonstrated no inflammatory cells in the alveolar bone on the buccal aspect of the first molar or in the surrounding tissues (Fig. 3) . The area of bone on the buccal aspect of the first molar was significantly increased ( P b 0.05) when both placebo and PGE 2 -containing pellets were implanted (Fig. 4A) . ANOVA showed that the area of alveolar bone was significantly increased in animals where doses of 0.1 and 0.05 mg/day were locally released during the 20-day experimental period ( P b 0.005) compared with the placebo group. No significant difference in bone area was observed between the placebo and 0.025 mg/day PGE 2 group. The lowest increase in buccal alveolar bone area was observed in the 0.025 mg/day PGE 2 group (Fig. 4A ).
Significant differences were found in the height and the width of the alveolar bone within different treatment groups when compared with the matched controls ( P b 0.05). However, when both Awa and Awp were compared by ANOVA, no significant differences were present between the different groups of treatment, although the highest values were noted for both measurements on those mandibles stimulated with the highest doses of PGE 2 (Figs. 4B and C). This was not the case for alveolar height, where significantly higher values were found for those mandibles treated with the two higher doses of PGE 2 compared with the placebo ( P b 0.05). The lowest dose of PGE 2 showed similar values to that of the placebo-treated group.
Bone remodeling indices
There was a significant increase in the proportion of dLS on the experimental side compared with the nonexperimental side ( P b 0.005). Nevertheless, ANOVA showed that the proportions of dLS were significantly higher ( P b 0.001) when the implanted pellet released a dose of 0.1 or 0.05 mg/ day of PGE 2 over 20 days compared with the placebo- treated group (Fig. 5A) . The proportion of dLS was significantly lower in the alveolar bone of those mandibles stimulated with 0.025 mg/day of PGE 2 compared with placebo ( P b 0.05).
A significant decrease in the proportion of RS was observed on the experimental side compared with the nonexperimental side in the 0.1 and 0.05 mg/day PGE 2 groups ( P b 0.01), but not in those treated with 0.025 mg/ day of PGE 2 or placebo. ANOVA showed that the proportion of RS in the alveolar bone was significantly lower in those mandibles treated with 0.1 and 0.05 mg/day compared with the placebo-treated group ( P b 0.005) (Fig.  5A) . When the data from the placebo-and 0.025 mg/day of PGE 2 -treated mandibles were compared, no significant difference was observed ( P N 0.05).
Mineral appositional rate, calculated as the amount of bone (Am) mineralized per day during the experimental period, showed that there was a significant increase in MAR in the alveolar bone of those animals treated with PGE 2 . This significant difference was higher in those animals treated with 0.1 and 0.05 mg/day of PGE 2 ( P b 0.005) when compared with matched controls, than in those animals treated with 0.025 mg/day of PGE 2 ( P b 0.05). No significant difference was observed for this index in the animals implanted with a placebo pellet ( P N 0.05). When data from the experimental sides were compared by ANOVA (Fig. 5B) , a significantly higher MAR occurred in mandibles stimulated with 0.1 and 0.05 mg/day of PGE 2 compared with those stimulated with placebo ( P b 0.05). No significant differences in MAR were recorded between mandibles treated with placebo and those treated with 0.025 mg/day of PGE 2 , even though a slight reduction in MAR was noted in those animals stimulated with the lowest dose of PGE 2 (Fig. 5B) .
BFR index analyzed by paired t test showed a significant increase in BFR during the experimental period when the mandibles were stimulated either with placebo or PGE 2 . ANOVA reported significant higher values in BFR in those animals treated with 0.1 and 0.05 mg/day of PGE 2 compared with those treated with placebo ( P b 0.001) (Fig. 5C ). The lowest value in BFR was observed in those mandibles treated with 0.025 mg/day of PGE 2 ( Fig. 5C) , and there was no significant difference in BFR between this group and the placebo-treated group ( P N 0.05).
Discussion
The results from the present study have shown that PGE 2 locally delivered adjacent to the mandible over a 20-day period induced alveolar bone formation, and this effect may be produced with doses as low as 0.05 mg/day. Prostaglandin E 2 is known to stimulate bone formation in long bones [3, 6, 7] , and the dose required to produce this positive effect may be as low as 0.3 mg/kg per day in load-bearing bones [15] . The animals used in this experiment weighed about 200 g. If the dose locally delivered to the mandible is associated with the animals' weight, 0.1 and 0.05 mg correspond to 0.5 and 0.25 mg/kg applied daily. In this context, the dose used in this experiment may be similar to that proposed for stimulating bone formation in load-bearing bones [13] . As the mandible exercises through mastication, low doses of PGE 2 may be used to stimulate bone formation when no pathological conditions are present. Thus, doses as low as 0.25 mg/kg per day applied locally for a 20-day period may be used to stimulate bone formation in the alveolar bone.
Morphometrical analysis reported an increase in the alveolar bone area following pellet implantation. This may be the result of a stimulatory effect induced by the pellet carrier (the contents were not released by the pellet manufacturer) or as a response to inflammation associated with the procedure. The authors propose the response is related to the pellet carrier rather than to inflammation, as the surgery was atraumatic and no postsurgical inflammation or irritation was observed. Inflammation associated with pellet surgery is more likely to be located in the soft tissue rather than in the mineralized tissues. However, the area of alveolar bone at the buccal aspect adjacent to the mesial root of the first molar in the mandible of those animals treated with the two highest doses of PGE 2 (0.1 and 0.05 mg/day) was significant greater than that observed in animals treated with 0.025 PGE 2 mg/day or placebo. These results showed that PGE 2 induced localized alveolar bone formation in the mandible similar to that observed in long bones [3, 6, 7] , and were consistent with the effect of PGE1 in the mandible [10, 11, 14, 17] . It should be noted that the mandible was not injured during pellet implantation, there was no evidence of inflammation in the soft tissues following healing and at the end of the experimental period. In addition, no inflammatory cells were evident in histological tissue sections. Thus, in this study, exogenous PGE 2 stimulated alveolar bone formation in normal physiological conditions. However, in the presence of trauma or inflammation, localized and long-term application of low dose PGE 2 may not promote bone formation but rather bone resorption and tissue loss.
An increase in alveolar bone area is the result of an increase in the dimensions of the bone on the buccal aspect. An increase in alveolar bone area in the buccal aspect on the experimental side was observed in all animals after pellet implantation. This is the result of significant increases in the height and the width of the alveolar bone on the side of pellet implantation when compared with their matched controls. Nevertheless, comparing the different groups of treatment by ANOVA, significant higher alveolar bone areas were observed at the buccal aspect in those mandibles stimulated with the two highest doses of PGE 2 . Alveolar bone height was significantly greater in those animals treated with the two higher doses of PGE 2 compared with those treated with 0.025 PGE 2 mg/day or placebo. Although there were no significant differences in width of the alveolar bone (Awa and Awp) between those animals treated with PGE 2 and those treated with placebo, a wider bone was observed in those animals treated with the higher doses of PGE 2 (0.1 and 0.05 mg/day). Thus, the significantly higher alveolar bone areas found in the buccal aspect of those animals treated with the two higher doses of PGE 2 results from a significant increase in the height of the alveolar bone associated to a wider alveolar bone. This suggests that PGE 2 may affect bone turnover in such a way that alveolar bone height is affected more than alveolar bone width, which means bone turnover may be affected at different sites. Although this study showed that when PGE 2 was locally applied to the mandible, it had a positive effect on alveolar bone height and area, further studies are required to determine if this reaction may be further developed for a therapeutic application.
The bone remodeling cycle is composed of two phases, bone deposition and bone resorption, which maintain bone turnover [12] . The duration of the remodeling cycle in the mandibular alveolar bone is shorter than in the long bones [18] . In the long bones, the remodeling cycle is 20-30 days [7] , whereas in the alveolar bone, it is 6 days plus a 5-day resting period [17] . The experimental period in this study extended for 20 days, implying that two remodeling cycles occurred. Bone remodeling indices showed that the two higher doses of PGE 2 increased MAR and BFR compared with the placebo, and thus, more mineralized tissue was deposited during the experimental period. This effect is associated with a decrease in the proportion of RS. The combined effect of PGE 2 -stimulated bone deposition and decreased bone resorption leads to the higher proportion of dLS observed when the mandibles were treated with 0.1 and 0.05 mg/day of PGE 2 . A significant increase in the proportion of dLS associated with a significant decrease in the proportion of RS suggests that PGE 2 has an effect on both sides of the remodeling cycle, shifting the cycle to increased bone formation [14] . Though these results are not conclusive for a role of PGE 2 on the remodeling cycle and on the bone cells, it may be hypothesized that PGE 2 affects the differentiation process and physiology of osteoblasts and osteoclasts, and so affects the remodeling rates.
Bone modeling is defined as the process by which the size or the shape of bone is changed in response to either intrinsic or extrinsic influences [4] . Whereas, bone remodeling consists of the removal and replacement of bone, and does not affect size or shape of that particular remodeled area [4, 12] . This study showed that PGE 2 locally delivered on the mandible at doses of 0.1 and 0.05 mg/day produced an increase in the size of the alveolar bone after 20 days of treatment. In other words, the effect of PGE 2 on the alveolar bone in the mandible produced a change in the size of this bone by affecting its dimensions. Furthermore, PGE 2 appears to affect bone turnover at different sites. The effect of PGE 2 on the alveolar bone may be described as a modeling-dependent bone gain, which may be due to new bone formation directly on the bone surface and at different locations [15] . This modeling-dependent bone gain stimulated by PGE 2 has been described previously in long bones [3] , and this study showed that it also occurs in the mandible. Nevertheless, the eicosanoid may not be only responsible for these results as the effect of PGE 2 low doses on new bone formation at different surface locations has been associated to an interaction between loading (local tissue strains) and drug treatment [13] .
Conclusions
The present study demonstrates that PGE 2 induced alveolar bone formation when it is locally delivered to the mandible over 20 days at doses of 0.1 and 0.05 mg/day. The results shown may be due to an action of PGE 2 on the remodeling cycle, increasing bone deposition while reducing bone resorption, as well as stimulating new bone formation on the bone surface. This effect of PGE 2 appears to be associated with local tissue strains. Further studies are necessary to understand the action of PGE 2 on the bone cells.
